Document is current
Any future updates will be listed below
-
Authors
Xiong, Yuquan
Taleb, Meriem https://orcid.org/0009-0002-7820-6829
Misawa, Kyohei
Hou, Zhaohua
Banerjee, Srijita
Amador-Molina, Alfredo
Jones, David R. https://orcid.org/0000-0002-3318-0146
Chintala, Navin K. https://orcid.org/0000-0003-4229-0977
Adusumilli, Prasad S. https://orcid.org/0000-0002-1699-2046
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (P30 CA008748)
Foundation for the National Institutes of Health (R01 CA236615-01)
Foundation for the National Institutes of Health (R01 CA235667)
Foundation for the National Institutes of Health (U01 CA214195)
U.S. Department of Defense (CA170630)
U.S. Department of Defense (CA180889)
U.S. Department of Defense (CA200437)
- License Information
-
More Information
Article History
Received: 30 June 2022
Accepted: 8 May 2023
First Online: 19 June 2023
Competing interests
: Y.X. and P.S.A. have a pending patent application on the KITv mutation as a co-stimulatory domain to use in T cells. P.S.A. declares research funding from ATARA Biotherapeutics and Novocure; is a scientific advisory board member and consultant for Adjuvant Genomics, ATARA Biotherapeutics, Abound Bio, Bio4t2, Carisma Therapeutics, Imugene, ImmPACT Bio, Johnson & Johnson, Link Immunotherapeutics, Orion Pharma, Outpace Bio, Pluri-biotech, Putnam Associates and Verismo Therapeutics; has patents, royalties and intellectual property on MSLN-targeted CAR and other T cell therapies licensed to ATARA Biotherapeutics; has issued a patent method for the detection of cancer cells using virus; and has pending patent applications on PD-1 dominant-negative receptors, a wireless pulse-oximetry device and an ex vivo malignant pleural effusion culture system. All other authors declare no competing interests. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to MSLN-targeted CARs and T cell therapies to ATARA Biotherapeutics and has associated financial interests.
